Similar articles

• Reduction in physician reimbursement and use of hormone therapy in prostate cancer.

  Elliott SP, Jarosek SL, Wilt TJ, Virnig BA. Elliott SP, et al. J Natl Cancer Inst. 2010 Dec 15;102(24):1826-34. doi: 10.1093/jnci/djq417. Epub 2010 Dec 3. J Natl Cancer Inst. 2010. PMID: 21131577 Free PMC article.
• Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

  Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Seidenfeld J, et al. Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Evid Rep Technol Assess (Summ). 1999. PMID: 11098244 Free PMC article.
• Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.

  [No authors listed] [No authors listed] Prescrire Int. 2007 Dec;16(92):243. Prescrire Int. 2007. PMID: 18092407
• [Total androgen blockade].

  Namiki M, Mizokami A. Namiki M, et al. Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8. Nihon Rinsho. 2002. PMID: 12599570 Review. Japanese. No abstract available.
• Timing of androgen deprivation therapy: some questions answered, others not.

  Schellhammer PF. Schellhammer PF. J Natl Cancer Inst. 2006 Jun 21;98(12):802-3. doi: 10.1093/jnci/djj257. J Natl Cancer Inst. 2006. PMID: 16788149 No abstract available.